RT Book, Section A1 Zeybek, Burak A1 Soble, Whitney A1 Ratner, Elena A2 Llor, Xavier A2 Hofstatter, Erin Wysong SR Print(0) ID 1182365721 T1 Risk Assessment and Clinical Management – Uterine Cancer T2 Cancer Genetics: A Clinical Approach YR 2022 FD 2022 PB McGraw Hill PP New York, NY SN 9781260440270 LK hemonc.mhmedical.com/content.aspx?aid=1182365721 RD 2024/11/14 AB Uterine cancer is the most common gynecologic malignancy in the United States, with an estimated 63,230 new cases and 11,350 deaths from the disease every year.1 Based on the data from its national cancer database, and Surveillance, Epidemiology and End Results (SEER), the lifetime risk of endometrial cancer is 2.8% and the average age at diagnosis is 62.2 As opposed to ovarian malignancies, the majority of the cases are diagnosed at an early stage (67% at stage I), as more than 90% of women with uterine cancer have an early presenting symptom (abnormal uterine bleeding).3 The most common histologic subtype is adenocarcinoma of the endometrium, which is subcategorized into two distinct groups that differ in incidence, response to therapy and prognosis.4 Type I tumors (80% of endometrial carcinomas), have more favorable outcomes due to grade 1 or 2 endometrioid histology, early stage at diagnosis, retention of hormone receptor status and younger age at onset. On the other hand, type II tumors (20% of endometrial cancers) portend a poorer prognosis, as these represent grade 3 endometrioid tumors and tumors of non-endometrioid histology such as serous, clear cell, mucinous, squamous, transitional cell, mesonephric and undifferentiated. They often lack hormone receptors and there is no clear association with estrogen stimulation.